Orally effective ion chelators

Abstract

Abstract Compounds are described of the general formula: ##STR1## wherein: R 1 is acyl of the formula --C(═O)--R 5 ; R 2 , R 3 , R 4 , R 6 , R 7 and R 8 are each selected from the group consisting of hydrogen and acyl of the formula: --C(═O)--R.sub.5 wherein R 5 is selected from the group consisting of alkyls, substituted alkyls, alkenyls, substituted alkenyls, cycloalkyls, substituted cycloalkyls, arylalkylenes, substituted arylalkylenes, alkylenecycloalkyls, alkylene substituted cycloalkyls, alkynyls, substituted alkynyls, aryls and substituted aryls, wherein R 2 , R 3 and R 4 are selected such that at least one of R 2 , R 3 and R 4 is an acyl. When R 2 , R 3 and R 4 include one or more acyls that are not identical to the acyl of R 1 , these compounds of formula I are novel compounds. The invention also includes processes to produce the compounds of formula I. Compounds of formula I complex and/or chelate tissue tri-valent ions, especially iron and aluminum (Fe +++ , Al +++ ), when administered to a human being, and are therefore useful in therapy in the treatment of diseases in which tissue ion levels in the body have increased or toxic levels. These iron-related diseases include, for example, thalassemia major, sideroachrestic anemic, Blackfan-Diamond anemia, aplastic anemia, sickle cell anemia, hemolytic anemias and hemosiderosis brought about by multiple blood transfusions including treatment for the anemia accompanying conditions requiring kidney dialysis. Aluminum-related diseases or conditions include Alzheimer's disease, senile dementia and dialysis encephalopathy.

Inventors

• 👤 Donald E. Green

Bibliographic Details